Shares of ProMetic Life Sciences Inc. (TSE:PLI – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of C$0.00 and traded as high as C$13.72. ProMetic Life Sciences shares last traded at C$13.60, with a volume of 921 shares traded.
ProMetic Life Sciences Stock Performance
The company has a current ratio of 4.06, a quick ratio of 3.66 and a debt-to-equity ratio of 37.47. The company has a market capitalization of C$317.06 million and a P/E ratio of -0.22. The stock has a 50-day moving average of C$13.60.
ProMetic Life Sciences Company Profile
Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals.
Featured Articles
- Five stocks we like better than ProMetic Life Sciences
- How to Calculate Return on Investment (ROI)
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- Conference Calls and Individual Investors
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- What is the S&P 500 and How It is Distinct from Other Indexes
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
